Karyopharm Therapeutics, Inc. (KPTI)
7.14
+0.14
(+2.00%)
USD |
NASDAQ |
Dec 12, 10:45
Karyopharm Therapeutics Research and Development Expense (TTM): 130.89M for Sept. 30, 2025
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| TG Therapeutics, Inc. | 142.90M |
| Actinium Pharmaceuticals, Inc. | 20.82M |
| Axsome Therapeutics, Inc. | 188.68M |
| Krystal Biotech, Inc. | 55.37M |
| Akebia Therapeutics, Inc. | 42.02M |